PE20060777A1 - Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas - Google Patents
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticasInfo
- Publication number
- PE20060777A1 PE20060777A1 PE2005001476A PE2005001476A PE20060777A1 PE 20060777 A1 PE20060777 A1 PE 20060777A1 PE 2005001476 A PE2005001476 A PE 2005001476A PE 2005001476 A PE2005001476 A PE 2005001476A PE 20060777 A1 PE20060777 A1 PE 20060777A1
- Authority
- PE
- Peru
- Prior art keywords
- prevention
- treatment
- indolinone
- fibrotic diseases
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
REFERIDA A COMPUESTOS DE INDOLINONA DE FORMULA I, DONDE X ES O O S; R1 ES H O UN GRUPO PROFARMACO; R2 ES CARBOXI, ALCOXI C1-C6-CARBONILO, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C7, ENTRE OTROS; R4 ES CICLOALQUILO C3-C7; R6 ES H, F, CIANO, AMINO, ENTRE OTROS; R5 ES H, ALQUILO C1-C3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-Z-[1-(4-(PIPERIDIN-1-IL-METIL)-ANILINO)-1-FENIL-METILENO]-6-ETOXICARBONIL-2-INDOLINONA, 3-Z-[(1-(4-(PIPERIDIN-1-IL-METIL)-ANILINO)-1-FENIL-METILENO]-6-CARBAMOIL-2-INDOLINONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO O PREVENCION DE ENFERMEDADES FIBROTICAS ESPECIFICAS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04030770 | 2004-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20060777A1 true PE20060777A1 (es) | 2006-10-06 |
Family
ID=36602118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2005001476A PE20060777A1 (es) | 2004-12-24 | 2005-12-16 | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
Country Status (33)
Country | Link |
---|---|
US (7) | US20060142373A1 (es) |
EP (4) | EP2384751B1 (es) |
JP (1) | JP5122976B2 (es) |
KR (1) | KR101235094B1 (es) |
CN (1) | CN101087605B (es) |
AR (1) | AR052177A1 (es) |
AU (1) | AU2005318126B2 (es) |
BE (1) | BE2015C038I2 (es) |
CA (1) | CA2591083C (es) |
CY (3) | CY1113766T1 (es) |
DK (2) | DK2878297T3 (es) |
EA (1) | EA015011B1 (es) |
ES (2) | ES2399270T3 (es) |
FR (1) | FR15C0046I2 (es) |
HK (1) | HK1110526A1 (es) |
HR (1) | HRP20130059T1 (es) |
HU (2) | HUE050998T2 (es) |
IL (1) | IL184125A (es) |
LT (2) | LT2878297T (es) |
LU (1) | LU92762I2 (es) |
ME (1) | ME01493B (es) |
MY (1) | MY148108A (es) |
NO (4) | NO339784B1 (es) |
NZ (1) | NZ556681A (es) |
PE (1) | PE20060777A1 (es) |
PL (2) | PL1830843T3 (es) |
PT (2) | PT2878297T (es) |
RS (1) | RS52653B (es) |
SI (2) | SI1830843T1 (es) |
TW (1) | TWI418351B (es) |
UA (1) | UA94390C2 (es) |
WO (1) | WO2006067165A2 (es) |
ZA (1) | ZA200703601B (es) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060154939A1 (en) * | 2004-12-24 | 2006-07-13 | Boehringer Ingelheim International Gmbh | Medicaments for the Treatment or Prevention of Fibrotic Diseases |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
WO2008152013A1 (en) * | 2007-06-12 | 2008-12-18 | Boehringer Ingelheim International Gmbh | Indolinone derivatives and their use in treating disease-states such as cancer |
US8338422B2 (en) | 2007-06-21 | 2012-12-25 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
DK2299987T3 (en) | 2008-06-06 | 2018-05-22 | Boehringer Ingelheim Int | Pharmaceutical Capsule Dosage Form Containing A Suspension Formulation Of An Indolinone Derivative |
KR101760657B1 (ko) * | 2008-06-06 | 2017-07-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 병용물 |
AU2015227503B2 (en) * | 2008-06-06 | 2017-02-23 | Boehringer Ingelheim International Gmbh | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | Фармацевтична лікарська форма для негайного вивільнення похідної індолінону | |
US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
BRPI0916432A2 (pt) * | 2008-07-29 | 2016-02-16 | Boehringer Ingelheim Int | compostos |
US8802384B2 (en) * | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
EP2429520A1 (en) * | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of oncological and fibrotic diseases |
JP2012526767A (ja) * | 2009-05-14 | 2012-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌及び線維性疾患の処置における新規な併用療法 |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
US8381108B2 (en) * | 2010-06-21 | 2013-02-19 | Microsoft Corporation | Natural user input for driving interactive stories |
WO2012021974A1 (en) | 2010-08-20 | 2012-02-23 | The Hospital For Sick Children | Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing |
CN103102352B (zh) * | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
CN103130775B (zh) * | 2011-11-22 | 2015-09-30 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
ES2748873T3 (es) | 2012-01-26 | 2020-03-18 | Angion Biomedica Corp | Compuestos antifibróticos y usos de los mismos |
CN103848814B (zh) * | 2012-12-06 | 2016-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的取代吲哚满酮衍生物 |
US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
CN104003925B (zh) * | 2013-06-05 | 2016-03-30 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
WO2015009889A1 (en) * | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
CA3172586A1 (en) * | 2013-07-31 | 2015-02-05 | Avalyn Pharma Inc. | Aerosol imatininb compounds and uses thereof |
US10450295B2 (en) * | 2013-08-09 | 2019-10-22 | Acclaim BioMed USA LLC | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis |
MX2016010213A (es) | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
CN106432042A (zh) * | 2015-08-13 | 2017-02-22 | 南京华威医药科技开发有限公司 | 尼达尼布乙磺酸水合物的药物新晶型 |
CN108367165B (zh) * | 2015-10-07 | 2022-03-04 | 艾葳生物科技有限公司 | 治疗皮肤纤维化病症的组合物和方法 |
DK3722291T3 (da) | 2015-12-24 | 2023-09-18 | Respivert Ltd | Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme |
CN107019697A (zh) * | 2016-02-02 | 2017-08-08 | 瑞阳(苏州)生物科技有限公司 | 预防或治疗纤维化疾病的药物组合物及其应用 |
US10669235B2 (en) | 2016-03-08 | 2020-06-02 | Respivert Limited | Indole derivatives and their use as protein kinase inhibitors |
JP2019511547A (ja) | 2016-04-13 | 2019-04-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 結腸直腸癌を治療するためのニンテダニブ、トリフルリジンおよびチピラシルの医薬組合せ |
EP3246029A1 (en) | 2016-05-19 | 2017-11-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer |
WO2017203027A1 (en) | 2016-05-27 | 2017-11-30 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
WO2017207643A1 (en) | 2016-06-01 | 2017-12-07 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
CA3029811A1 (en) * | 2016-07-08 | 2018-01-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Indoline derivatives and method for using and producing the same |
CN108066343A (zh) * | 2016-11-08 | 2018-05-25 | 瑞阳(苏州)生物科技有限公司 | 一种预防或治疗肾纤维化疾病的药物 |
JP2019536812A (ja) * | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
CN106692150B (zh) * | 2016-12-21 | 2019-08-20 | 中国人民解放军第三〇二医院 | 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途 |
US20190388407A1 (en) * | 2017-02-12 | 2019-12-26 | Aiviva Biopharma, Inc. | Multikinase inhibitors of vegf and tfg beta and uses thereof |
EP3600322A1 (en) | 2017-03-28 | 2020-02-05 | Boehringer Ingelheim International GmbH | Nintedanib for use in methods for the treatment of muscular dystrophy |
CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
EA202090977A1 (ru) * | 2017-10-23 | 2020-09-04 | Бёрингер Ингельхайм Интернациональ Гмбх | Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild) |
CN112135612A (zh) | 2018-03-07 | 2020-12-25 | 普利安特治疗公司 | 氨基酸化合物和使用方法 |
JP7061310B2 (ja) * | 2018-04-05 | 2022-04-28 | 国立大学法人 大分大学 | 慢性脂肪性疾患の予防および治療用医薬 |
US11534399B2 (en) | 2018-04-23 | 2022-12-27 | Inspirmed Corp. | Inhalable liposomal sustained release composition for use in treating pulmonary diseases |
CN108358827A (zh) * | 2018-05-07 | 2018-08-03 | 日照市普达医药科技有限公司 | 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法 |
TWI764186B (zh) | 2018-06-15 | 2022-05-11 | 漢達生技醫藥股份有限公司 | 激酶抑制劑之鹽類及其組合物 |
CN109134431B (zh) * | 2018-10-10 | 2021-06-04 | 成都理工大学 | 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物 |
GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
KR20220109439A (ko) | 2019-12-04 | 2022-08-04 | 이도르시아 파마슈티컬스 리미티드 | 섬유증 질환의 치료에서 사용하기 위한 아제티딘 lpa1 수용체 길항제와 피르페니돈 및/또는 닌테다닙의 조합 |
US20230135671A1 (en) | 2020-04-01 | 2023-05-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
CA3171349A1 (en) | 2020-04-08 | 2021-10-14 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
GB202006079D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
GB202006074D0 (en) | 2020-04-24 | 2020-06-10 | Vicore Pharma Ab | New composition |
CA3185027A1 (en) | 2020-05-28 | 2021-12-02 | Mission Therapeutics Limited | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mi tochondrial dysfunction |
WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
CA3186148A1 (en) | 2020-06-08 | 2021-12-16 | Mission Therapeutics Limited | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4460581A (en) | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
WO1992012154A1 (en) | 1990-12-31 | 1992-07-23 | Fujisawa Pharmaceutical Co., Ltd. | Imidazotriazine derivatives |
GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
US5716972A (en) | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
US5656644A (en) | 1994-07-20 | 1997-08-12 | Smithkline Beecham Corporation | Pyridyl imidazoles |
GB9303993D0 (en) | 1993-02-26 | 1993-04-14 | Fujisawa Pharmaceutical Co | New heterocyclic derivatives |
US5593991A (en) | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
US5670527A (en) | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
WO1995009847A1 (en) | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
US5728708A (en) | 1993-10-01 | 1998-03-17 | Novartis Corporation | Pharmacologically active pyridine derivatives and processes for the preparation thereof |
EP0672042B1 (en) | 1993-10-01 | 2006-05-03 | Novartis AG | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
WO2000023072A1 (en) | 1998-10-20 | 2000-04-27 | Omeros Medical Systems, Inc. | Irrigation solution containing mapk inhibitors and their use for treating pain and inflammation |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
TW449590B (en) | 1995-04-14 | 2001-08-11 | Boehringer Ingelheim Kg | New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
US6140332A (en) | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
IL123950A (en) | 1995-10-06 | 2001-04-30 | Merck & Co Inc | Transformed imidazoles with anti-cancer and cytokine-inhibiting activity and pharmaceutical preparations containing them |
AU7482396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
WO1997016442A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
ES2205167T3 (es) | 1996-01-11 | 2004-05-01 | Smithkline Beecham Corporation | Nuevos compuestos de imidazol sustituidos. |
AP9700912A0 (en) | 1996-01-11 | 1997-01-31 | Smithkline Beecham Corp | Novel cycloalkyl substituted imidazoles |
JP2001508395A (ja) | 1996-01-11 | 2001-06-26 | スミスクライン・ビーチャム・コーポレイション | 新規シクロアルキル置換イミダゾール |
ZA97175B (en) | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
DE19608665A1 (de) | 1996-03-06 | 1997-09-11 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
US6096748A (en) | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
WO1997035855A1 (en) | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
US6096739A (en) | 1996-03-25 | 2000-08-01 | Smithkline Beecham Corporation | Treatment for CNS injuries |
JP2000504023A (ja) | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
WO1997047618A1 (en) | 1996-06-10 | 1997-12-18 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
WO1998006715A1 (en) | 1996-08-09 | 1998-02-19 | Smithkline Beecham Corporation | Novel piperazine containing compounds |
DE19633640C2 (de) | 1996-08-21 | 1999-05-06 | Ford Global Tech Inc | Vorrichtung zur Winkelverstellung einer Welle gegenüber einem Antriebsrad |
WO1998007425A1 (en) | 1996-08-21 | 1998-02-26 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
IL129928A0 (en) | 1996-11-19 | 2000-02-29 | Amgen Inc | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
EP0959886A4 (en) | 1996-11-20 | 2001-05-02 | Merck & Co Inc | TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS |
HUP0001140A3 (en) | 1996-12-05 | 2002-05-28 | Amgen Inc Thousand Oaks | Substituted pyrimidinone and pyridone compounds and methods of use |
JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
WO1998028292A1 (en) | 1996-12-23 | 1998-07-02 | Smithkline Beecham Corporation | Novel piperidine containing compounds |
JP3573757B2 (ja) | 1997-01-29 | 2004-10-06 | ファイザー・インク | スルホニルウレア誘導体、およびインターロイキン−1の活性を制御する上でのスルホニルウレア誘導体の使用 |
WO1998047899A1 (en) | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
DE69816109T2 (de) | 1997-04-24 | 2004-04-22 | Ortho-Mcneil Pharmaceutical, Inc. | Substituierte imidazole zur behandlung von entzündlichen krankheiten |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
CA2289102A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
JP2002502380A (ja) | 1997-05-22 | 2002-01-22 | ジー.ディー.サール アンド カンパニー | p38キナーゼ阻害剤としてのピラゾール誘導体 |
HUP0001880A3 (en) | 1997-05-22 | 2002-03-28 | G D Searle & Co Chicago | Substituted pyrazoles as p38 kinase inhibitors |
BR9809451A (pt) | 1997-05-22 | 2000-06-20 | Searle & Co | Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38. |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
DE1019040T1 (de) | 1997-05-23 | 2001-02-08 | Bayer Ag | Hemmung von p38 kinase aktivität durch arylharnstoff |
CA2291065C (en) | 1997-05-23 | 2010-02-09 | Bayer Corporation | Raf kinase inhibitors |
AU742293B2 (en) | 1997-06-12 | 2001-12-20 | Aventis Pharma Limited | Imidazolyl-cyclic acetals |
EP1023066A4 (en) | 1997-06-13 | 2001-05-23 | Smithkline Beecham Corp | NEW PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUND |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
IL133766A0 (en) | 1997-06-30 | 2001-04-30 | Ortho Mcneil Pharm Inc | 2-substituted imidazoles useful in the treatment of inflammatory diseases |
US5939421A (en) | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
WO1999001452A1 (en) | 1997-07-02 | 1999-01-14 | Smithkline Beecham Corporation | Novel cycloalkyl substituted imidazoles |
AR016294A1 (es) | 1997-07-02 | 2001-07-04 | Smithkline Beecham Corp | Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion |
TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
US5981710A (en) | 1997-07-21 | 1999-11-09 | Baxter International, Inc. | Therapeutic hemoglobin composition having isotropically increased size |
GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
PT1017378E (pt) | 1997-09-23 | 2003-04-30 | Astrazeneca Ab | Derivados de amida para o tratamento de doencas mediadas por citoquinas |
US5975738A (en) | 1997-09-30 | 1999-11-02 | Lsi Logic Corporation | Method for detecting failure in redundant controllers using a private LUN |
WO1999017776A1 (en) | 1997-10-08 | 1999-04-15 | Smithkline Beecham Corporation | Novel cycloalkenyl substituted compounds |
CN1285830A (zh) | 1997-11-14 | 2001-02-28 | 三共株式会社 | 吡啶基吡咯衍生物 |
CA2314980A1 (en) | 1997-12-19 | 1999-07-01 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses |
DK1043995T3 (da) | 1997-12-22 | 2007-03-05 | Bayer Pharmaceuticals Corp | Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer |
MXPA00006233A (es) | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
ATE297383T1 (de) | 1997-12-22 | 2005-06-15 | Bayer Pharmaceuticals Corp | Hemmung der p38 kinase unter verwendung von symmetrischen und asymmetrischen diphenylharnstoffen |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
AU759297B2 (en) | 1998-02-26 | 2003-04-10 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrrolobenzimidazoles for treating inflammatory diseases |
CN1305846C (zh) | 1998-03-26 | 2007-03-21 | 参天制药株式会社 | 脲衍生物 |
DE19815020A1 (de) | 1998-04-03 | 1999-10-07 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19816624A1 (de) | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
JP3590586B2 (ja) | 1998-05-05 | 2004-11-17 | エフ.ホフマン−ラ ロシュ アーゲー | P−38mapキナーゼインヒビターとしてのピラゾール誘導体 |
US6316466B1 (en) | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
WO1999058523A1 (en) | 1998-05-14 | 1999-11-18 | G.D. Searle & Co. | 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
AU749293B2 (en) | 1998-05-15 | 2002-06-20 | Astrazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
KR100628284B1 (ko) | 1998-05-15 | 2006-09-27 | 아스트라제네카 아베 | 시토킨 매개 질환 치료용 벤즈아미드 유도체 |
US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
US6340685B1 (en) | 1998-05-22 | 2002-01-22 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
PL344330A1 (en) | 1998-05-22 | 2001-10-22 | Smithkline Beecham Corp | Novel 2-alkyl substituted imidazole compounds |
KR100605140B1 (ko) | 1998-05-22 | 2006-07-28 | 싸이오스 인크 | 심장병 및 다른 질병을 치료하기 위한 헤테로 고리 화합물및 그 치료 방법 |
CA2333157A1 (en) | 1998-05-26 | 1999-12-02 | Smithkline Beecham Corporation | Novel substituted imidazole compounds |
DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
WO1999064400A1 (en) | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
AU4395399A (en) | 1998-07-02 | 2000-01-24 | Sankyo Company Limited | Five-membered heteroaryl compounds |
US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
NZ509318A (en) | 1998-08-04 | 2002-10-25 | Astrazeneca Ab | Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines |
KR100663143B1 (ko) | 1998-08-05 | 2007-01-02 | 산텐 세이야꾸 가부시키가이샤 | 질소 포함 방향족 헤테로고리를 갖는 신규 우레아 유도체 |
WO2000010563A1 (en) | 1998-08-20 | 2000-03-02 | Smithkline Beecham Corporation | Novel substituted triazole compounds |
IL141724A0 (en) | 1998-08-28 | 2002-03-10 | Scios Inc | INHIBITORS OF P38-α KINASE |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
EP1114039A1 (en) | 1998-09-18 | 2001-07-11 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
AR023659A1 (es) | 1998-09-18 | 2002-09-04 | Vertex Pharma | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos |
DE19842833B4 (de) | 1998-09-18 | 2005-04-14 | Merckle Gmbh | 2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung |
DE59906030D1 (de) | 1998-09-25 | 2003-07-24 | Boehringer Ingelheim Pharma | Neue substituierte indolinone mit einer inhibierenden wirkung auf verschiedene kinasen und cyclin/cdk-komplexe |
SK285520B6 (sk) | 1998-09-25 | 2007-03-01 | Astrazeneca Ab | Amidové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie na prípravu liečiva na liečbu stavov sprostredkovaných cytokínmi |
KR20010089284A (ko) | 1998-10-01 | 2001-09-29 | 다비드 에 질레스 | 화합물 |
AU6476599A (en) | 1998-11-03 | 2000-05-22 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
WO2000025791A1 (en) | 1998-11-04 | 2000-05-11 | Smithkline Beecham Corporation | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
ATE262523T1 (de) | 1998-11-20 | 2004-04-15 | Searle Llc | Verfahren zur herstellung 5-substituierter pyrazole unter verwendung von dithietane |
AU3114600A (en) | 1998-12-16 | 2000-07-03 | Vertex Pharmaceuticals Incorporated | Crystallized p38 complexes |
ATE227719T1 (de) | 1998-12-16 | 2002-11-15 | Aventis Pharma Ltd | Heteroaryl-zyklische acetale |
CN1326848C (zh) | 1998-12-25 | 2007-07-18 | 帝国脏器制药株式会社 | 氨基吡唑衍生物 |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
ES2251360T3 (es) | 1999-03-12 | 2006-05-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos heterociclicos aromaticos en calidad de agentes antiinflamatorios. |
ID30176A (id) | 1999-03-12 | 2001-11-08 | Boehringer Ingelheim Pharma | Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi |
PL200804B1 (pl) | 1999-03-17 | 2009-02-27 | Astrazeneca Ab | Pochodne amidowe, sposoby ich wytwarzania, ich kompozycje farmaceutyczne oraz ich zastosowanie |
CZ20013276A3 (cs) | 1999-03-17 | 2001-12-12 | Astrazeneca Ab | Nové amidové deriváty, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
US6492516B1 (en) | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
ATE376547T1 (de) | 1999-05-21 | 2007-11-15 | Scios Inc | Derivate des indol-typs als p38 kinase inhibitoren |
DE19924401A1 (de) | 1999-05-27 | 2000-11-30 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
AU775285B2 (en) | 1999-06-21 | 2004-07-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof |
US6403596B1 (en) | 1999-06-28 | 2002-06-11 | Merck & Co., Inc. | Substituted pyridones having cytokine inhibitory activity |
EP1202957B1 (en) | 1999-07-16 | 2004-09-29 | Leo Pharma A/S | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
RU2247719C2 (ru) | 1999-07-16 | 2005-03-10 | Лео Фармасьютикал Продактс Лтд.А/С (Левенс Кемиске Фабрик Продукционсактиесельскаб) | Аминобензофеноны как ингибиторы il-1 бета и tnf-альфа, фармацевтическая композиция и способ лечения и/или профилактики воспалительных заболеваний |
ATE277897T1 (de) | 1999-07-16 | 2004-10-15 | Leo Pharma As | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha |
SI1210320T1 (en) | 1999-07-16 | 2005-02-28 | Leo Pharma A/S | Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
PL353645A1 (en) | 1999-07-16 | 2003-12-01 | Leo Pharma A/Sleo Pharma A/S | Novel aminobenzophenones |
US6794395B1 (en) | 1999-08-27 | 2004-09-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituted indolinones, their manufacture and their use as medicaments |
UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
EP1224321A2 (en) | 1999-10-13 | 2002-07-24 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | A method of screening for substances acting on msk1 |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
DE19949209A1 (de) | 1999-10-13 | 2001-04-19 | Boehringer Ingelheim Pharma | In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
ES2277858T3 (es) | 1999-10-21 | 2007-08-01 | F. Hoffmann-La Roche Ag | Heterociclos de nitrogeno biciclicos alquilamino sustituidos como inhibidores de proteina kinasa p38. |
CZ20021744A3 (cs) | 1999-10-21 | 2002-08-14 | F. Hoffmann-La Roche Ag | Bicyklické dusíkové heterocykly substituované heteroalkylaminoskupinou jako inhibitory P38 proteinkinázy |
JP2003513977A (ja) | 1999-11-10 | 2003-04-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換2−アリール−3−(ヘテロアリール)−イミダゾ[1,2−α]ピリミジン類および関連薬剤組成物および方法 |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
CA2389360C (en) | 1999-11-16 | 2008-06-03 | Steffen Breitfelder | Urea derivatives as anti-inflammatory agents |
AU1782301A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors |
ATE296809T1 (de) | 1999-11-23 | 2005-06-15 | Smithkline Beecham Corp | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren |
EP1248624A4 (en) | 1999-11-23 | 2003-01-22 | Smithkline Beecham Corp | 3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS |
US7053099B1 (en) | 1999-11-23 | 2006-05-30 | Smithkline Beecham Corporation | 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors |
EE200200275A (et) | 1999-11-30 | 2003-10-15 | Pfizer Products Inc. | Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid |
WO2001042189A1 (en) | 1999-12-06 | 2001-06-14 | Leo Pharma A/S | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
EP1242385B1 (en) | 1999-12-28 | 2009-11-25 | Pharmacopeia, Inc. | Cytokine, especially tnf-alpha, inhibitors |
DE20002820U1 (de) | 2000-02-16 | 2000-05-25 | Igus Gmbh | Energieführungskette |
CA2401190A1 (en) | 2000-02-23 | 2001-08-30 | Iconix Pharmaceuticals, Inc. | Pyridine-amidines as modulators of p38 map kinase |
AU2001241927A1 (en) | 2000-02-28 | 2001-09-12 | Scios Inc. | Inhibitors of p38-alpha kinase |
AR035851A1 (es) | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
ATE350378T1 (de) | 2000-04-08 | 2007-01-15 | Boehringer Ingelheim Pharma | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
DE10042059A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10042060A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10042062A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung |
DE10042058A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10051320A1 (de) | 2000-10-17 | 2002-04-25 | Boehringer Ingelheim Pharma | Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
DE10054019A1 (de) | 2000-11-01 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
US6638965B2 (en) | 2000-11-01 | 2003-10-28 | Boehringer Ingelheim Pharma Kg | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions |
DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
MXPA04009536A (es) | 2002-03-30 | 2005-01-25 | Boehringer Ingelheim Pharma | Compuestos heterociclos biciclicos, composiciones farmaceuticas que contienen estos compuestos, su utilizacion y procesos para su preparacion. |
DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
US20040204458A1 (en) | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
US7148249B2 (en) | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
US20060154939A1 (en) | 2004-12-24 | 2006-07-13 | Boehringer Ingelheim International Gmbh | Medicaments for the Treatment or Prevention of Fibrotic Diseases |
PE20061155A1 (es) | 2004-12-24 | 2006-12-16 | Boehringer Ingelheim Int | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas |
KR101760657B1 (ko) | 2008-06-06 | 2017-07-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 약제학적 병용물 |
-
2005
- 2005-12-16 PE PE2005001476A patent/PE20060777A1/es not_active Application Discontinuation
- 2005-12-20 US US11/275,223 patent/US20060142373A1/en not_active Abandoned
- 2005-12-21 EP EP10184949.5A patent/EP2384751B1/en active Active
- 2005-12-21 UA UAA200708383A patent/UA94390C2/ru unknown
- 2005-12-21 ES ES05823930T patent/ES2399270T3/es active Active
- 2005-12-21 DK DK14190398.9T patent/DK2878297T3/da active
- 2005-12-21 PL PL05823930T patent/PL1830843T3/pl unknown
- 2005-12-21 CN CN2005800447033A patent/CN101087605B/zh active Active
- 2005-12-21 CA CA2591083A patent/CA2591083C/en active Active
- 2005-12-21 WO PCT/EP2005/057002 patent/WO2006067165A2/en active Application Filing
- 2005-12-21 KR KR1020077017058A patent/KR101235094B1/ko active IP Right Grant
- 2005-12-21 NZ NZ556681A patent/NZ556681A/en unknown
- 2005-12-21 EP EP14190398.9A patent/EP2878297B1/en active Active
- 2005-12-21 LT LTEP14190398.9T patent/LT2878297T/lt unknown
- 2005-12-21 DK DK05823930.2T patent/DK1830843T3/da active
- 2005-12-21 PT PT141903989T patent/PT2878297T/pt unknown
- 2005-12-21 HU HUE14190398A patent/HUE050998T2/hu unknown
- 2005-12-21 JP JP2007547503A patent/JP5122976B2/ja active Active
- 2005-12-21 PT PT58239302T patent/PT1830843E/pt unknown
- 2005-12-21 AU AU2005318126A patent/AU2005318126B2/en active Active
- 2005-12-21 PL PL14190398T patent/PL2878297T3/pl unknown
- 2005-12-21 ME MEP-2013-13A patent/ME01493B/me unknown
- 2005-12-21 RS RS20130037A patent/RS52653B/en unknown
- 2005-12-21 EP EP19209457.1A patent/EP3643309A1/en active Pending
- 2005-12-21 SI SI200531656T patent/SI1830843T1/sl unknown
- 2005-12-21 EP EP05823930A patent/EP1830843B1/en active Active
- 2005-12-21 SI SI200532279T patent/SI2878297T1/sl unknown
- 2005-12-21 EA EA200701175A patent/EA015011B1/ru not_active IP Right Cessation
- 2005-12-21 ES ES14190398T patent/ES2797546T3/es active Active
- 2005-12-22 MY MYPI20056170A patent/MY148108A/en unknown
- 2005-12-22 AR ARP050105468A patent/AR052177A1/es unknown
- 2005-12-23 TW TW094146425A patent/TWI418351B/zh not_active IP Right Cessation
-
2007
- 2007-05-04 ZA ZA200703601A patent/ZA200703601B/xx unknown
- 2007-06-21 IL IL184125A patent/IL184125A/en active IP Right Grant
- 2007-07-23 NO NO20073831A patent/NO339784B1/no active Protection Beyond IP Right Term
-
2008
- 2008-05-05 HK HK08104971.7A patent/HK1110526A1/xx not_active IP Right Cessation
-
2009
- 2009-12-22 US US12/645,151 patent/US20100204211A1/en not_active Abandoned
-
2013
- 2013-01-23 HR HRP20130059TT patent/HRP20130059T1/hr unknown
- 2013-01-30 CY CY20131100088T patent/CY1113766T1/el unknown
-
2014
- 2014-02-20 US US14/184,821 patent/US20140296217A1/en not_active Abandoned
-
2015
- 2015-06-29 BE BE2015C038C patent/BE2015C038I2/fr unknown
- 2015-06-30 LT LTPA2015025C patent/LTC1830843I2/lt unknown
- 2015-06-30 HU HUS1500034C patent/HUS1500034I1/hu unknown
- 2015-06-30 CY CY2015024C patent/CY2015024I1/el unknown
- 2015-07-02 LU LU92762C patent/LU92762I2/xx unknown
- 2015-07-03 FR FR15C0046C patent/FR15C0046I2/fr active Active
- 2015-12-29 US US14/982,179 patent/US10154990B2/en active Active
-
2016
- 2016-10-12 NO NO20161634A patent/NO341591B1/no unknown
-
2017
- 2017-06-12 NO NO20170945A patent/NO342914B1/no unknown
- 2017-07-28 NO NO2017035C patent/NO2017035I1/no unknown
-
2018
- 2018-10-23 US US16/167,567 patent/US20190038600A1/en not_active Abandoned
-
2020
- 2020-06-16 CY CY20201100551T patent/CY1123050T1/el unknown
- 2020-07-06 US US16/921,043 patent/US20200330435A1/en not_active Abandoned
-
2023
- 2023-08-02 US US18/363,779 patent/US20230372297A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
PE20080362A1 (es) | Derivados de ciclohexilpirazol-lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 | |
AR062111A1 (es) | Derivados de beta-d-glucopiranosil indol, metodo de preparacion, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
PE20091724A1 (es) | Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7 | |
PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
PE20061353A1 (es) | Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa | |
TW200612936A (en) | Indole derivatives | |
CY1108908T1 (el) | Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4 | |
PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
CY1110977T1 (el) | Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου | |
PE20091095A1 (es) | Moduladores de gamma secretasa | |
PE20091376A1 (es) | Derivados de fenilamino como moduladores de beta-amiloide | |
PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
PE20070491A1 (es) | Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina | |
PE20081316A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
PE20060623A1 (es) | Compuestos de sulfonamida como potenciadores del receptor de glutamato | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
PA8581401A1 (es) | Compuestos de imedazopiridina como agonistas del receptor 5-ht4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |